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ABSTRACT
Purpose: F14512 is an epipodophyllotoxin derivative from etoposide, combined 
with a spermine moiety introduced as a cell delivery vector. The objective of this 
study was to compare the safety and antitumor activity of F14512 and etoposide 
phosphate in dogs with spontaneous non-Hodgkin lymphoma (NHL) and to 
investigate the potential benefit of F14512 in P-glycoprotein (Pgp) overexpressing 
lymphomas.
Experimental Design: Forty-eight client-owned dogs with intermediate to high-
grade NHL were enrolled into a randomized, double-blind trial of F14512 versus 
etoposide phosphate. Endpoints included safety and therapeutic efficacy.
Results: Twenty-five dogs were randomized to receive F14512 and 23 dogs 
to receive etoposide phosphate. All adverse events (AEs) were reversible, and no 
treatment-related death was reported. Hematologic AEs were more severe with 
F14512 and gastrointestinal AEs were more frequent with etoposide phosphate. 
F14512 exhibited similar response rate and progression-free survival (PFS) as 
etoposide phosphate in the global treated population. Subgroup analysis of dogs with 
Pgp-overexpressing NHL showed a significant improvement in PFS in dogs treated 
with F14512 compared with etoposide phosphate.
Conclusion: F14512 showed strong therapeutic efficacy against spontaneous 
NHL and exhibited a clinical benefice in Pgp-overexpressing lymphoma superior to 
etoposide phosphate. The results clearly justify the evaluation of F14512 in human 
clinical trials.
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INTRODUCTION
Comparative oncology has shown that naturally 
occurring canine cancers are of valuable and translatable 
interest for the understanding of human cancer biology and 
the characterization of new therapies [1–3]. Dogs develop 
a broad spectrum of spontaneous occurring cancers that 
share strong similarities with human cancers, offering a 
singular opportunity to answer key questions (efficacy, 
safety, pharmacokinetic/pharmacodynamic, biomarkers) 
and guiding the cancer drug development path in a manner 
not possible using more conventional models [1–3].
Non-Hodgkin lymphomas (NHL) are among the 
most common hematopoietic cancers in both human and 
dog populations. Canine NHL share many biological and 
therapeutic similarities with their human counterparts, 
including clinical presentation, biological behavior, and 
therapeutic responses [4–6]. These similarities support the 
use of the canine model as a comparative, relevant large 
animal model to study new therapies for both human and 
canine benefit.
Multidrug resistance (MDR) is one major cause of 
treatment failure in most malignant hematopoietic cancers 
reported in dogs and humans, associated with high rates 
of mortality [7–10]. The most common mechanism of 
MDR is the overexpression of ATP binding cassette 
(ABC) transporters, which actively pump numerous 
chemotherapeutic drugs outside the cancer cells, 
attenuating drug efficacy and resulting in resistance to 
treatment [10–12]. The ABC transporter subfamily B 
member 1 (ABCB1/MDR1, P-glycoprotein, Pgp) is one of 
the most important transporters to confer MDR to cancer 
cells [13–16].
F14512 is an epipodophyllotoxin (etoposide) core 
combined with a spermine chain able to specifically target 
cancer cells with an active polyamine transport system 
(PTS) [17, 18]. The positively charged spermine tail 
contributes to (i) favoring the selective uptake of the drug 
by tumor cells via the PTS, (ii) increasing DNA binding to 
reinforce topoisomerase II inhibition, (iii) enhancing the 
water solubility of the drug [17–20]. The antiproliferative 
activity of F14512 has been demonstrated to be superior 
to etoposide in numerous human cancer cell lines such 
as breast cancer, non-small cell lung cancer, leukemia, 
melanoma, ovarian cancer and carcinomas [17, 21–24]. 
In a vinorelbine-resistant P388 mouse leukemia cell 
line model overexpressing high level of functional 
P-glycoproteins, F14512 displayed a strong antileukemic 
activity and the antitumor activity of F14512 was not 
impacted by the MDR status of cancer cells [Annereau JP, 
Brel V, Riquet W, Créancier L, Vandenberghe I, Fournier 
E, Robichon C, Stennevin A, Offrete V, Lacastaigneratte 
L, Gomes B, Kruczynski A, Bailly C, et al. Abstract 
988: F14512, a novel vectorized topoiserase II inhibitor, 
bypasses MDR1 mediated resistance. Abstract presented at 
the 104th Annual Meeting of the American Association for 
Cancer Research, Washington, DC, 6 to 10 April 2013]. 
These characteristics augured well for further development 
of the drug in malignant hematopoietic tumor patients.
On the basis of these preclinical data, we 
initially evaluated the safety, pharmacokinetic and 
pharmacodynamic profiles of F14512 in dogs with 
spontaneous NHL in a traditional 3+3 phase I dose-
escalation trial [25]. F14512 was well tolerated in dogs, 
and F14512 demonstrated a strong antitumor activity on 
canine NHL. The safety and tolerability of intravenous 
etoposide phosphate were also investigated to determine 
the maximum tolerated dose in dogs [26]. These results 
provided the rationale for the phase II, randomized, 
double-blind trial in dogs. The objective of this study was 
to compare the safety and antitumor activity of F14512 
and etoposide phosphate in dogs with spontaneous 
NHL and to investigate the potential benefit of F14512 
in P-glycoprotein overexpressing lymphomas, with 
the primary aim of showing that effectively designed 
comparative oncology studies would offer bidirectional 
benefit to both pet animals and humans with cancer.
RESULTS
Epidemiological and clinical characteristics
Between December 03, 2014 and August 30, 2016, 
48 dogs with naturally occurring intermediate to high-
grade NHL were enrolled in this randomized double-blind 
clinical trial. Forty-one (41/48, 85%) dogs had no prior 
treatment, and 7 (7/48, 15%) dogs were enrolled after a 
relapse following a CHOP-based chemotherapy protocol. 
Twenty-two (22/48, 46%) dogs with untreated NHL were 
randomized to receive F14512 and 19 (19/48, 40%) to 
receive etoposide phosphate. Three (3/48, 6%) dogs with 
relapsed NHL were randomized to receive F14512 and 
4 (4/48, 8%) to receive etoposide phosphate. The last 
day of follow-up was January 30, 2017. All dogs in both 
treatment groups received the same 8-week induction 
chemotherapy protocol, consisting of a 3-hour, once 
daily intravenous (IV) injection on 3 consecutive days, 
and every 2 weeks for 4 cycles. After completion of the 4 
cycles, dogs who experienced a clinical benefit (complete 
or partial response or stable disease) received 3 additional 
consolidation cycles with one intravenous injection of the 
same drug every 3 weeks (day 68, 89, and 110) (Figure 1). 
The main clinical characteristics were balanced between 
the two treatment groups and are summarized in Table 1. 
Dogs treated with F14512 were statistically younger than 
dogs treated with etoposide phosphate (mean ± SD: 6.6 ± 
2.5 years versus 8.5 ± 2.7 years, P = 0.016).
P-glycoprotein (Pgp) expression in tumor cells
P-glycoprotein expression was evaluated in all 
dog tumor cells by immunohistochemistry (IHC) using 
the monoclonal antibody C494 adapted from Lee and 
colleagues [13] (Figure 2). Twenty-eight (28/48, 59%) 
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dogs were classified with Pgp-positive tumors (Pgp+, 
high and moderate expression) and 16 (16/48, 33%) dogs 
were Pgp-negative (Pgp-, negative and low expression). In 
the group of dogs treated with F14512, 15 (15/25, 60%) 
dogs were Pgp+ and 8 (8/25, 32%) dogs were Pgp-. In the 
group of dogs treated with etoposide phosphate, 13 (13/23, 
57%) dogs were Pgp+ and 8 (8/23, 35%) dogs were Pgp-
P-glycoprotein expression could not be interpreted in 4 
(4/48, 8%) dogs. There were no significant differences in 
Pgp tumor expression between the two treatment groups 
(P = 1.0). In the group of dogs previously treated with 
CHOP-based chemotherapy, 3 (3/7, 43%) dogs were Pgp+, 
3 (3/7, 43%) were Pgp-, and one non evaluable.
Safety analysis
All 48 dogs were evaluated for safety analysis 
during the induction chemotherapy protocol over a period 
of 8 weeks. Thirteen (13/25, 52%) dogs completed the 
4-cycle induction protocol in the F14512 group and 15 
(15/23, 65%) dogs in the etoposide phosphate group. 
Twelve (12/25, 48%) dogs discontinued the protocol in 
Figure 1: Trial design. (A) Flow diagram for the trial. Enrollment of 48 dogs randomized to receive F14512 (n = 25) or etoposide 
phosphate (n = 23). (B) Schematics of study design. Black arrows indicate time of treatment administration. CR: complete response, E: 
etoposide phosphate, F: F14512, IV: intravenous, PD: progressive disease, PR: partial response, SD: stable disease.
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Table 1: Epidemiological and clinical characteristics of dogs randomized to receive F14512 (n = 25) or etoposide 
phosphate (n = 23)
Epidemiological characteristics Total F14512 Etoposide phosphate P value
Number of dogs (%) 48 (100%) 25 (100%) 23 (100%)
Prior treatment, no. (%) 0.696a
Untreated 41 (85%) 22 (88%) 19 (83%)
Prior chemotherapy 7 (15%) 3 (12%) 4 (17%)
Sex, no. (%) 0.087b
Male 27 (56%) 17 (68%) 10 (43%)
Female 21 (44%) 8 (32%) 13 (57%)
Age, years, mean ± SD (range) 7.5 ± 2.7 (3–14) 6.6 ± 2.5 (3–12) 8.5 ± 2.7 (5–14) 0.016c
Body weight, kg, mean ± SD (range) 28.5 ± 11.7 (8.0–
51.4)
31.5 ± 10.2 (8.0–
48.8)
25.3 ± 12.6 (8.6–
51.4)
0.067c
Clinical stage at inclusion, no. (%) 0.482a
Stage II 2 (4%) — 2 (9%)
Stage III 8 (17%) 4 (16%) 4 (17%)
Stage IV 29 (60%) 17 (68%) 12 (52%)
Stage V 9 (19%) 4 (16%) 5 (22%)
Clinical substage (systemic signs), no. 
(%)
0.398b
Substage a (absence) 26 (54%) 15 (60%) 11 (48%)
Substage b (presence) 22 (46%) 10 (40%) 12 (52%)
Immunophenotype, no. (%) 0.88a
B-cell 37 (77%) 20 (80%) 17 (74%)
T-cell 7 (15%) 3 (12%) 4 (17%)
Unclassified 4 (8%) 2 (8%) 2 (9%)
Cytomorphological Subtype, no. (%) 1.0a
- B-cell lymphoma:
DLBCL 33 (69%) 17 (68%) 16 (70%)
Transformed marginal zone lymphoma 2 (4%) 1 (4%) 1 (4%)
Burkitt-like 2 (8%) —
- T-cell lymphoma: 2 (4%)
T-cell Pleomorphic 1 (2%) — 1 (4%)
Large granular T-cell 1 (2%) 1 (4%) —
Transformed small clear cell, T-zone 1 (2%) — 1 (4%)
High-grade, small to medium cells, 
unspecified
3 (6%) 2 (8%) 1 (4%)
- Unclassified 5 (11%) 2 (8%) 3 (13%)
Pgp expression at inclusion, no. (%) 1.0a
Pgp- (neg and low) 16 (33%) 8 (32%) 8 (35%)
Pgp+ (mid and high) 28 (59%) 15 (60%) 13 (57%)
Unclassified 4 (8%) 2 (8%) 2 (8%)
DLBCL: Diffuse large B-cell lymphoma, Pgp: P-glycoprotein. (a) Fisher’s exact test; (b) Chi-square test; (c) t-test.
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the F14512 group, 4 dogs due to progressive disease, and 
8 dogs for death related to the disease. In the etoposide 
phosphate group, 8 (8/23, 35%) dogs did not complete 
the protocol, 4 for progressive disease and 4 dogs died 
due to the disease. Seventy-one cycles in the F14512 
group and 73 cycles in the etoposide phosphate group 
were evaluated and the type, frequency and severity of 
treatment-emergent adverse events (TEAE) were graded 
according to the Veterinary Cooperative Oncology 
Group criteria for adverse events (VCOG-CTCAE), 
version 1.1 [27]. Treatment-emergent adverse events 
included neutropenia, anemia, thrombocytopenia, and 
gastrointestinal disorders (diarrhea and vomiting). No 
other biological adverse events were reported. Incidences 
of TEAEs are summarized in Table 2. Most TEAEs were 
moderate in intensity and all TEAEs were reversible. 
Hematologic adverse events were more important in 
number and severity in the F14512 group than in the 
etoposide phosphate group (P < 0.001). Neutropenia was 
observed 4 to 14 days (median: 8 days) after F14512 
administration and 5 to 9 days (median: 8 days) after 
etoposide phosphate administration. Thrombocytopenia 
and anemia were reported 5 to 14 days after F14512 and 
etoposide phosphate administration. All thrombocytopenia 
and anemia events were asymptomatic and reversible. All 
non-hematological adverse events were gastrointestinal 
adverse events (diarrhea and vomiting) and were reported 
in 18 (18/25, 72%) dogs treated with F14512 and 22 
(22/23, 96%) dogs treated with etoposide phosphate. 
Gastrointestinal adverse events were more frequent in the 
etoposide phosphate group compared with the F14512 
group (P = 0.049). No hypersensitivity reactions were 
reported.
All adverse events were manageable, reversible 
and resulted in prolonged or early hospitalization for 10 
(10/25, 40%) dogs in the F14512 group (1 Grade 3 febrile 
neutropenia and 9 prolonged Grade 4 neutropenia) and 
for 1 (1/23, 4%) dog in the etoposide phosphate group 
(prolonged Grade 4 neutropenia). The median time of 
prolonged or early hospitalization was 3 days (range 111 
days). Adverse events resulted in treatment dose reduction 
for 7 (7/25, 28%) dogs in the F14512 group and for 1 
(1/23, 4%) dog in the etoposide phosphate group. No death 
related to treatment was reported.
Figure 2: P-glycoprotein expression evaluated by immunohistochemistry in lymph node tumor cells. Microscopic 
photographs of lymph node histology stained with a primary mouse anti-human P-glycoprotein clone C494 antibody (ALX-801–003-C100, 
lab Enzo life sciences). Original magnification ×40. Normal canine liver was used as a positive control for P-glycoprotein analysis. Non-
immune serum substituted to C494 on lymph node tissues was used as a negative control. Immunohistochemical score method was then 
evaluated by a scoring system adapted from Lee and colleagues as follows: negative (neg, less than 25% stained cells), low (more than 25% 
but less than 50% of the tumor cells are stained with a light staining), moderate (mid, more than 50% but less than 75% of the tumor cells 
are stained with moderate intensity), high (more than 75% are stained with a moderate to high intensity). Negative and Low Pgp expression 
was included in the Pgp- group; Mid and High expression was included in the Pgp+ group. Ab: antibody; Pgp: P-glycoprotein.
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Quality of life assessment, defined by a questionnaire 
completed by pet owners at day 0, 23 and 62, did not reveal 
any significant difference in quality of life between the two 
treatment groups (Supplementary Figure 1).
Efficacy endpoints
All 48 randomized dogs started the treatment 
(Figure 1). Nineteen (19/25, 76%) dogs treated with 
F14512 achieved an objective response with 12 CR and 
7 PR. In the etoposide phosphate group, 19 (19/23, 83%) 
dogs achieved an objective response with 9 CR and 10 PR. 
No significant difference was seen between the two groups 
(P = 0.73). The median time from randomization to best 
complete or partial response was very similar in the two 
groups: 26 days (range: 570 days) in F14512 group and 33 
days (range: 565) in etoposide phosphate group (P = 0.81).
At day 62, at the end of 4 cycles, the remission 
status was assessed based on CT-imaging according to the 
Response Evaluation Criteria in Solid Tumors version 1.0 
(RECIST) [28]. The overall response rate (day 62) was 
44% with 7 (7/25, 28%) dogs experiencing a CR and 4 
(4/25, 16%) dogs experiencing a PR in the F14512 group 
versus 48% with 7 (7/23, 31%) dogs experiencing a CR 
and 4 (4/23, 17%) dogs experiencing a PR in the etoposide 
phosphate group. There was no difference in overall 
response rate at day 62 between the two groups (P = 0.79).
Disease progression or death related to the disease 
was reported in all dogs. The median PFS for all dogs was 
86 days (range: 4224). The median PFS for dogs treated 
with F14512 was 86 days (range: 7224), and 91 days 
(range: 4202) for those treated with etoposide phosphate, 
with no statistical difference between the two groups 
(P = 0.30). Five dogs were still alive at the time of data 
analysis (3 dogs in F14512 group and 2 dogs in etoposide 
phosphate group) with a median time of follow-up of 139 
days (range: 84–153).
Analysis of the 28 randomly assigned dogs with 
Pgp-overexpressing lymphoma (Pgp+), 10 (10/15, 67%) 
dogs treated with F14512 achieved an objective response 
(6 CR and 4 PR) at day 62 compared to 5 (5/13, 38%) 
dogs treated with etoposide phosphate (3 CR and 2 
PR). Median PFS across treatments for dogs with Pgp-
overexpressing lymphoma (Pgp+) was 105 days (range: 
4–224). Median PFS for dogs with Pgp-overexpressing 
lymphoma (Pgp+) treated with F14512 was 139 days 
(range: 16–224) versus 91 days (range: 4–168) for 
dogs treated with etoposide phosphate. Kaplan-Meier 
curves for PFS are shown in Figure 3. Dogs with Pgp-
overexpressing lymphoma (Pgp+) treated with F14512 
were significantly more likely to have a longer PFS 
compared with dogs that received etoposide phosphate 
(HR: 0.42, 95%-CI: 0.17–0.99; P = 0.046).
Exploratory biomarkers
Tumor cell survival and γ-H2AX expression
Formation of γ-H2AX has been identified as an early 
event after the production of double-strand breaks and 
Table 2: Hematological and non-hematological adverse events graded according to the Veterinary Cooperative 
Oncology Group criteria for adverse events (VCOG-CTCAE), version 1.1
Adverse events
F14512 (71 cycles, 25 dogs) Etoposide phosphate (73 cycles, 23 dogs)
Grade 1–2 Grade 3 Grade 4 Grade 5 Grade 1–2 Grade 3 Grade 4 Grade 5
Number of cycles with hematological adverse events and febrile neutropenia, no. (%)
Neutropenia 19 (27%) 11 (15%) 27 (38%) 0 (0%) 20 (27%) 4 (5%) 2 (3%) 0 (0%)
Thrombocytopenia 16 (23%) 5 (7%) 4 (6%) 0 (0%) 12 (16%) 1 (1%) 0 (0%) 0 (0%)
Anemia 29 (41%) 3 (4%) 2 (3%) 0 (0%) 31 (42%) 0 (0%) 0 (0%) 0 (0%)
Febrile neutropenia 0 (0%) 1 (1%) 9 (13%) 0 (0%) 0 (0%) 0 (0%) 1 (1%) 0 (0%)
Number of dogs with hematological adverse events and febrile neutropenia, no. (%)
Neutropenia 3 (12%) 5 (20%) 15 (60%) 0 (0%) 8 (35%) 4 (17%) 2 (9%) 0 (0%)
Thrombocytopenia 5 (20%) 4 (16%) 3 (12%) 0 (0%) 7 (30%) 1 (4%) 0 (0%) 0 (0%)
Anemia 15 (60%) 2 (8%) 2 (8%) 0 (0%) 16 (70%) 0 (0%) 0 (0%) 0 (0%)
Febrile neutropenia 0 (0%) 1 (4%) 9 (36%) 0 (0%) 0 (0%) 0 (0%) 1 (4%) 0 (0%)
Number of dogs with non-hematological adverse events, no. (%)
Gastrointestinal 
adverse events
18 (72%) 0 (0%) 0 (0%) 0 (0%) 22 (96%) 0 (0%) 0 (0%) 0 (0%)
Vomiting 5 (20%) 0 (0%) 0 (0%) 0 (0%) 17 (74%) 0 (0%) 0 (0%) 0 (0%)
Diarrhea 17 (68%) 0 (0%) 0 (0%) 0 (0%) 21 (91%) 0 (0%) 0 (0%) 0 (0%)
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has been widely used as a tool to measure induced DNA 
damage caused by cytotoxic chemical agents [29, 30]. We 
examined the possibility that expression of γ-H2AX after 
treatment initiation might be used as a surrogate indicator 
of DNA damage response.
Total surviving cells count and the proportion 
of γ-H2AX nuclear staining were measured by flow 
cytometry prior to treatment and following the ðrst 
injection of F14512 or etoposide phosphate to determine if 
treatment administration was associated with any cytotoxic 
effect. Serial fine-needle aspirates were performed in 
tumoral lymph nodes before treatment administration and 
two, four and 52 hours following the first drug injection. 
The total surviving cells count in these serial aspirates 
was evaluated using Trypan blue exclusion method and 
normalized to the aspirate volume.
A rapid and significant decrease in the number of 
total surviving cells was observed in the two treatment 
groups, as early as 4 hours after the initiation of the 
F14512 administration and after 52 hours after the 
beginning of etoposide phosphate administration 
(Figure 4A). Thirty-six dogs have pretreatment γ-H2AX 
nuclear expression interpretable (median: 30.73%, 
range: 0.59–83.16). Two (H2) and four hours (H4) after 
treatment initiation, surviving cells showed persistent 
elevated expression of γ-H2AX in both treatment groups 
(Figure 4B). A more than 10% increase of γ-H2AX nuclear 
positive surviving cells was observed in 11 dogs, as early 
as 4 hours after the beginning of F14512 and etoposide 
phosphate administration. In these 11 dogs, 8 (8/11, 73%) 
experienced a clinical response (5 CR, 3 PR). Among 
the non-responders with γ-H2AX nuclear expression 
interpretable (5 SD, 3 PD), static or decrease percentage 
of γ-H2AX nuclear positive surviving cells was observed 
in 6 (6/8, 62.5%) dogs 4 hours after the beginning of 
drug administration. No differences between F14512 and 
etoposide treatment groups were identified.
Serum thymidine kinase 1 activity (sTK1)
Serum thymidine kinase 1 (sTK1) activity has 
been shown to correlate with the proliferative activity 
of cancer cells providing information regarding 
prognosis and treatment effectiveness in human 
patients with hematologic malignancies [31–33]. To 
evaluate sTK1 activity as a potential blood biomarker 
of treatment efficacy, we measured sTK1 activity prior 
to treatment initiation, at the time of the best clinical 
response and at the time of relapse. Pretreatment 
sTK1 activity demonstrated a high degree of variation 
(median: 1374 Du/L, range: 20–60005, Supplementary 
Table 1). Pretreatment sTK1 activity was higher in 
dogs with B-cell lymphoma (P < 0.001), in dogs with 
clinical substage b (P = 0.025) and in dogs with Pgp-
overexpressing lymphoma (P = 0.013). Pretreatment 
sTK1 activity was not correlated with the other clinical 
characteristics.
After treatment initiation, sTK1 activity decreased 
significantly when dogs experienced an objective tumor 
response (P < 0.001) and increased again at the time of 
relapse (P < 0.001) (Figure 4C). Serum TK1 activity 
was significantly lower in dogs with complete versus 
partial response (median: 20 vs. 312 Du/L, P = 0.003; 
Figure 4D).
Pretreatment plasma D-dimer levels
Here, we investigated the correlation between 
pretreatment plasma D-dimer levels and PFS. The median 
value of pretreatment plasma D-dimer concentration was 
Figure 3: Kaplan-Meier curves by treatment group for progression-free survival. (A) The entire cohort, n = 48. (B) Dogs 
with Pgp-overexpressing lymphoma (Pgp+), n = 28. Log-rank P values are shown.
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0.4 μg/mL (range: 0.1–14.3). The optimal cut-off value 
of D-dimer based on PFS was 0.5 μg/mL (HR: 2.218, 
95%-CI: 1.175–4.187, P = 0.014). Pretreatment D-dimer 
levels > 0.5 μg/mL were not correlated with clinical 
characteristics (Supplementary Table 2). Median PFS for 
dogs with a pretreatment D-dimer level > 0.5 μg/mL was 
54 days (range: 4–153) compared with 104 days (range: 
10–224) for dogs with a D-dimer level ≤ 0.5 μg/mL. A 
pretreatment D-dimer level > 0.5 μg/mL was significantly 
associated with inferior PFS (P = 0.011, Figure 4E). In 
the multivariate Cox regression model, a D-dimer level 
> 0.5 μg/mL remained an independent predictor for 
worse PFS (HR: 3.197, 95%-CI: 1.536–6.655, P = 0.002, 
Table 3).
DISCUSSION
The results of the present study provide evidence 
that naturally occurring cancer in dogs offers a unique 
opportunity for preclinical modeling to develop innovative 
therapies for human [3]. Here, we report the results of a 
randomized, double blind trial comparing the safety and 
antitumor activity of F14512 and etoposide phosphate in 
dogs with spontaneous NHL.
The administration of F14512 and etoposide 
phosphate demonstrated an acceptable safety profile in 
dogs and most adverse events were consistent with those 
expected with dose-intense chemotherapy. All TEAEs 
were reversible and no death related to treatment was 
reported. These results were consistent with the safety 
and tolerability data of F14512 and etoposide phosphate 
previously evaluated in dogs with lymphoma [25, 26] and 
revealed a similar safety proðle compared with clinical 
toxicology studies performed in humans. In the ðrst-in-man 
phase I trial of F14512 in adult human relapsed/refractory 
acute myeloid leukemia, hematologic toxicity was the 
major adverse event identified, including neutropenia 
(18%), febrile neutropenia (10%) and thrombocytopenia 
(5%) [De Botton S, Berthon C, Bulabois C, Prebet T, Vey 
N, Chevallier P. F14512 a novel polyamine-vectorized 
anti-cancer drug targeting topoisomerase II in adults 
patients with acute myeloid leukemia (AML): results from 
a Phase 1 study. Abstract presented at the 17th Congress 
of the European Hematology Association, Amsterdam, 
The Netherlands, 14 to 17 June 2012]. In human patients 
receiving etoposide, nausea and vomiting were the major 
gastrointestinal toxicities reported [34]. As in human 
patients, severe acute hypersensitivity reactions, caused 
Figure 4: Exploratory biomarkers. (A) Total surviving cells count measured by flow cytometric analysis at H0, H2, H4 and H52 
following treatment initiation. Drug infusion was started at H0. The horizontal bars represent median. (B) Percentage of γ-H2AX expression 
in surviving cells at H0, H2, H4 following treatment initiation. Groups were compared using Wilcoxon rank test. (C) Serum thymidine 
kinase 1 activity (Du/L) in dogs prior to treatment initiation (n = 48), at the time of the best clinical response (n = 36) and at the time 
of progressive disease (n = 30). Minimum detectable activity for this assay: 20 Du/L. The horizontal bars represent median. (D) Serum 
thymidine kinase 1 activity in dogs with complete (CR, n = 20) and partial (PR, n = 12) response. Minimum detectable activity for this 
assay: 20 Du/L. The horizontal bars represent median. Levels of sTK1 activity between groups were compared using Wilcoxon rank test. 
(E) Kaplan-Meier curve in dogs with high (> 0.5 μg/mL, n = 21) or low (≤ 0.5 μg/mL, n = 27) pretreatment D-dimer levels. Log-rank P 
value is shown.
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by histamine release probably associated with the vehicle 
(polysorbate-80) used for the parenteral formulation, have 
been previously reported in dogs treated with etoposide 
(VP-16) [35, 36]. Etoposide phosphate is a water-soluble 
pro-drug of etoposide formulated without polysorbate-80 
and no hypersensitivity reactions were reported in dogs 
during the protocol. This safety analysis demonstrates that 
clinical trials in dogs can provide an opportunity to assess 
toxicity data as a bridge to human therapeutics.
This study also confirmed the antitumor activity of 
F14512 and etoposide phosphate in spontaneous NHL in 
dogs. Both F14512 and etoposide phosphate induced an 
early decrease of tumoral lymph node cells and a high 
clinical response rate of 76% (19/25) and 83% (19/23) 
respectively. As a vectorized form of etoposide, F14512 
had shown strong antitumor activity in vitro study [17] 
and superior therapeutic efficacy in xenograft mice models 
compared with etoposide [19, 20]. In our randomized 
double-blind trial, F14512 showed a comparable 
therapeutic efficacy to etoposide phosphate in term of 
response rate and PFS in the global treated population. 
This result might be explained by the better than expected 
outcome in etoposide phosphate group. Etoposide was 
previously shown to have a minimal therapeutic effect in 
a retrospective study on 13 dogs with naturally occurring 
lymphomas, with only 2 dogs (2/13, 15%) displaying a 
partial response [35]. We previously demonstrated that 
the IV formulation of etoposide phosphate improved the 
safety and tolerability of the drug in dogs with a maximum 
tolerated dose of 300 mg/m2 with daily IV infusion at 
100 mg/m2, during 3 consecutive days every 2 weeks 
[26]. Here, we confirmed a valuable improvement of the 
therapeutic effect of etoposide phosphate for the treatment 
of lymphoma in dogs with an overall response rate of 
83% compared with 15% in previous study. The observed 
clinical response of F14512 and etoposide phosphate 
reported here is comparable to the clinical response 
of doxorubicin, commonly recognized as the most 
efficient single-agent for the treatment of canine high-
grade lymphoma, and associated with overall response 
rates reported from 74% to 84% [37–40]. Our study 
provides evidence that F14512 and etoposide phosphate 
demonstrate therapeutic potential in canine lymphoma, 
which should be further investigated either alone or in 
combination with other agents in dogs in this indication.
F14512 was also shown to be a poor substrate of 
the efflux protein Pgp. In the present study, the subgroup 
analysis of Pgp-overexpressing tumors showed a 
significant improvement in PFS in dogs with naturally Pgp-
overexpressing NHL compared with etoposide phosphate. 
Progression-free survival was used as a primary endpoint 
because most of veterinary cancer patients do not die from 
their disease but are euthanized by their owners due to poor 
quality of life or financial limitations. This makes overall 
survival analysis much less robust than in human trials. 
This finding has important clinical implications. Indeed, 
following standard dose-intense chemotherapy, relapsed 
or refractory lymphomas develop chemotherapeutic 
multidrug resistance [10–12]. High expression of ABC-
transports and P-glycoprotein in particular, has been 
associated with a decreased response to cytotoxic drugs, 
and a poor prognosis in human malignant hematopoietic 
tumors [15]. We evaluated the Pgp expression in naturally 
occurring tumor cells by IHC as previously described in 
canine lymphoma [7, 13, 41, 42] and the present study 
confirmed for the first time the superior antitumor activity 
of F14512 to etoposide phosphate in naturally occurring 
Pgp-overexpressing lymphomas in dogs. On the basis of 
these results, F14512 appears to be a potentially promising 
candidate for human clinical trials. F14512 has progressed 
to clinical development in human refractory/relapsing 
acute myeloid leukemia and ovarian cancer [43].
Table 3: Univariate and multivariate analysis of prognostic factors for progression-free survival
Variable
Univariate analysis Multivariate analysis
HR (95%CI) P value HR (95%CI) P value
Sex (male vs. female) 1.692 (0.943–3.038) 0.078
Age (> 7 years vs. ≤ 7 years) 1.563 (0.862–2.837) 0.142
Previous chemotherapy (yes vs. no) 2.711 (1.159–6.343) 0.021 8.371 (2.968- 23.613) < 0.001
Stage (V vs. II+III+IV) 2.746 (1.267–5.954) 0.011 2.242 (0.982–5.119) 0.055
Systemic signs (b vs. a) 1.266 (0.711–2.257) 0.423
Immunophenotype (T vs. B) 2.198 (0.931–5.190) 0.072
Morphotype (DLBCL vs. others) 0.362 (0.185–0.709) 0.003 0.289 (0.142–0.586) 0.001
Pgp (Pgp+ vs. Pgp-) 0.631 (0.335–1.190) 0.155
D-dimer level (> 0.5 vs. ≤ 0.5 mg/mL) 2.218 (1.175–4.187) 0.014 3.197 (1.536–6.655) 0.002
Treatment group (F14512 vs. Etoposide) 0.732 (0.403–1.332) 0.307
DLBCL: Diffuse large B-cell lymphoma, Pgp: P-glycoprotein.
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Biomarker studies, including γ-H2AX cytometry 
analysis, serum thymidine kinase 1 activity and 
pretreatment D-dimer level, revealed that spontaneous 
occurring lymphomas in dogs share clinical and 
biological similarities with their human counterparts, 
and provide opportunities to optimize drug development 
by generating relevant biomarker data unavailable 
with human xenografts or genetically engineered mice 
models [4–6]. Repeated analysis of γ-H2AX expression 
by flow cytometry was evaluated as a marker for DNA 
damage following treatment administration. In our study, 
the increase of γ-H2AX after drug administration was 
particularly higher in dogs who experienced a clinical 
response and the results confirmed that γ-H2AX can be 
useful for elucidating the pharmacodynamics of cytotoxic 
drugs and tumor targeting agents in dogs. Our study also 
demonstrated that sTK1 activity provides information 
regarding treatment response and disease progression, 
confirming previously results described in human NHL 
[31]. Monitoring sTK1 activity could help to detect 
complete responders and disease progression in dogs 
with lymphoma [44]. Pretreatment D-dimer levels have 
been reported to correlate with poor prognosis in several 
types of human malignancies, including DLBCL [45], 
however, the clinical significance of D-dimer has been 
rarely reported in dogs. This study demonstrated that 
high pretreatment D-dimer levels were independently 
associated with inferior PFS. D-dimer level, as a routinely 
used and easily measured marker, could serve as a useful 
prognostic predictor in clinical practice for both human 
and canine NHL.
Limitations of this study include the small number 
of dogs and the heterogeneity in morphological subtypes 
of canine lymphomas. However, randomized, double-
blinded trial may overcome limitations of small sample 
size and yield valid conclusions [46, 47]. In the current 
study, the main clinical characteristics were balanced 
between the two treatment arms including sex, weight, 
stage, substage, immunophenotype, cytomorphological 
subtype, Pgp expression and prior treatment received. 
Dogs treated with F14512 were statistically younger 
than dogs treated with etoposide phosphate. However, no 
correlation was found between age and PFS and therefore, 
results in this present study would not be expected to have 
been significantly affected by the age of the dogs in the 
two treatment arms.
This study provided valuable preclinical evidence 
for the therapeutic potential of F14512 against NHL, 
however further clinical development in human resistant/
refractory NHL would be warranted. Other molecular 
factors implicated in multidrug resistance and not 
evaluated in this study have been described in humans, 
including expression of breast cancer resistance proteins 
(BCRP), multidrug resistance-associated proteins 1 
(MRP1), lung resistance proteins (LRP), p53 gene 
mutation and BCL-2 gene expression [10, 11, 15, 48–51].
In conclusion, the data reported here illustrate that 
spontaneous cancers in dogs offer a unique opportunity 
to integrate pet dog studies into the development paths of 
new cancer drugs. The final outcome of clinical trials in 
dogs would allow early assessment of drug activity and 
toxicity, and the identification and validation of biological 
endpoints and surrogate markers to provide significant 
rationale for future human clinical trials.
MATERIALS AND METHODS
Study design
The study design was prospective, randomized 
and double-blinded (dog’s owner-blind, investigator-
blind) to compare the safety and the antitumor activity 
of F14512 with etoposide phosphate in dogs with NHL. 
The study design and the management of the data were 
carried out by OCR (Oncovet-Clinical-Research), 
Parc Eurasanté, Loos 59120, France. The clinical trial 
was conducted at Oncovet, Villeneuve d’Ascq 59650, 
France. F14512 was provided by Pierre Fabre Research 
Institute (Pierre Fabre Médicament, Toulouse 31100, 
France). The design and synthesis of F14512 have been 
patented (WO2005/100363). Etoposide phosphate, 
Etopophos®, was purchased from Bristol-Myers Squibb 
Pharmaceuticals Limited.
Dog selection
The trial was available for client-owned dogs 
presenting with a histologically and/or cytologically 
confirmed diagnosis of intermediate to high-grade NHL. 
Dogs were considered eligible for inclusion if they (i) had 
new or previously diagnosed intermediate to high-grade 
NHL; (ii) had a measurable disease at the time of inclusion 
(allowing staging and clinical response assessment); 
(iii) had relapsed to standard therapies or whose owners 
had declined standard treatment; (iv) had no anticancer 
drug in the month before the inclusion (including steroids); 
(v) had no significant biochemical abnormality or blood 
cytopenia, which precluded the use of cytotoxic drugs; 
(vi) had no concurrent serious systemic disorder with an 
expected survival time of at least 9 weeks, according to the 
veterinary subjective assessment.
After enrolment, dogs were excluded of the trial 
in case of disease progression, severe adverse event, 
or withdrawal on owner or investigator decision, and a 
CHOP-based chemotherapy protocol was offered to 
the dog’s owner. Data collection was stopped after the 
exclusion or death of the last dog included in the study.
Ethical approval was obtained from the OCR 
(Oncovet-Clinical-Research) Ethical Committee before 
trial initiation. The protocol was performed in compliance 
with applicable local, national and international animal 
welfare regulations and adhered to the highest standards 
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of animal care and use. Dogs were handled according to 
principles outlined in the National Institutes of Health 
(NIH) Guide for the Care and Use of Laboratory Animals. 
Written informed consent form was obtained from the 
owner before enrollment of each dog. Owners were 
permitted to withdraw their dog from the trial at any time.
Randomization and masking
At enrollment, dogs were stratified regarding prior 
chemotherapy received (untreated vs. previously treated 
lymphoma) and randomly assigned to receive F14512 
or etoposide phosphate in a ratio 1:1. It was planned to 
randomize 48 dogs. The randomization sequence was 
generated by an individual person who was independent of 
the study team by use of computer program. Investigators 
and dog’s owners were blinded to the treatment assignment.
Procedures
Initial staging
At enrollment, all dogs were staged based on the 
modified WHO five-stage criteria for canine lymphoma. 
Initial staging tests included a complete blood count, 
biochemistry panel, whole-body CT-scan, peripheral 
lymph nodes fine-needle aspirates (FNA) and biopsies, 
ultrasound-guided liver and spleen FNA, urine analysis 
and a bone marrow aspirates. Bone marrow was considered 
infiltrated if neoplastic lymphoid cells represented ≥ 3% of 
all nucleated cells on the basis of bone marrow cytology 
[52]. Definitive diagnosis was confirmed for each dog 
with lymph node cytological examination by one board-
certified clinical pathologist (C. Fournel-Fleury) and 
lymphoma was graded according to the updated Kiel 
morphological classification [53]. Immunophenotyping 
was performed using immunohistochemistry as previously 
described [25]. Cytology and immunophenotype were 
recorded for all dogs.
Treatment schedule
All the dogs involved in the study followed the 
same induction chemotherapy protocol over a period of 
8 weeks (Figure 1). Dogs were randomly assigned to 
receive F145120.075 mg/kg, or etoposide phosphate100 
mg/m2, delivered over a 3-hour intravenous (IV) infusion 
once daily on 3 consecutive days for 4 cycles, every 2 
weeks (days 1–3, days 15–17, days 29–31, days 43–45). 
After completion of the 4 cycles, dogs who experienced 
a clinical benefit (complete or partial response or stable 
disease) received 3 additional consolidation cycles with 
one intravenous injection of the same drug every 3 weeks 
(day 68, 89, and 110).
The maximum tolerated dose of F14512 and 
etoposide phosphate was previously evaluated using 
two independent traditional 3+3 phase I dose-escalation 
trials [25, 26]. Dogs were hospitalized for 5 days during 
each cycle (days 1–5, days 15–19, days 29–33, and 
days 43–47). The prescribed dose was diluted in sterile 
saline solution for a total volume of 50 mL and was not 
discernable from the investigators and the healthcare team. 
The drug was administered IV through an indwelling 
catheter placed into a cephalic vein. No premedication was 
administered before the IV administration.
Safety analysis
Safety analysis was evaluated in all dogs during 
the induction chemotherapy protocol over a period of 8 
weeks. Safety evaluation were TEAEs, laboratory safety 
assessments and quality of life evaluation. Treatment-
emergent adverse events were assessed at each scheduled 
visit and graded according to the VCOG-CTCAE, 
version 1.1 [27]. The adverse event grade assigned to 
each dog was based on the highest grade of hematologic 
toxicity reported, and the highest grade of gastrointestinal 
or constitutional signs noted. Owners were questioned 
about signs of adverse clinical effects using a quality of 
life questionnaire adapted from Lynch and colleagues and 
completed at day 0, 23 and 62 [54]. A complete blood 
count was performed before and 7 days after each cycle. 
Recovery of absolute neutrophil count to 1500 cells per 
µL and platelet count to 50 000 platelets per µL was 
required before starting each cycle. Dogs with prolonged 
(> 48 hours) asymptomatic grade 4 neutropenia, febrile 
neutropenia, and grade 3 gastrointestinal adverse events, 
the dose was reduced by 20%. If the neutrophils count was 
lower than 1500/µL or the platelets count was lower than 
50 000/µL at the time of the next cycle, the chemotherapy 
administration was postponed for one week. If a delay of 
more than 2 weeks occurred, treatment was discontinued. 
A prophylactic broad-spectrum antibiotic therapy was 
administrated for dogs with grade ≥ 3 asymptomatic 
neutropenia. Dogs with febrile neutropenia, and grade 
≥ 3 gastrointestinal adverse events were hospitalized and 
treated with intravenous fluids and antibiotics.
Response assessment and follow-up
Response was evaluated before each chemotherapy 
administration. The best response to treatment was 
determined based on physical examination and peripheral 
lymph node size measurement using a caliper, according 
to the VCOG Response Evaluation Criteria for Peripheral 
Nodal Lymphoma in dogs version 1.0 [55]. At the end of 
4 cycles (day 62), dogs underwent a complete end-staging 
and response to treatment were defined according to the 
RECIST, version 1.0 [28]. Bone marrow aspirations were 
repeated if infiltrated at enrollment.
A complete response (CR) was deðned as the 
disappearance of all measurable disease (i. e. lymph 
nodes returned to a size considered non-pathologic in the 
judgement of the evaluator and no new sites of disease 
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should be observed). A partial response (PR) was deðned 
as at least 30% reduction in the sum of widest diameters 
of peripheral lymph nodes measured at enrollment. Stable 
disease (SD) was deðned after 4 cycles of treatment as 
<30% reduction or <20% increase in the sum of the widest 
diameters of the peripheral lymph nodes measured at 
enrollment. Progressive disease (PD) was deðned as >20% 
increase in the sum of the widest diameters of measurable 
peripheral lymph nodes or the appearance of new lesions. 
Progressive disease was confirmed with cytological 
evidence of lymphoma on lymph node aspirate.
Follow-up continued every 4 weeks from completion 
of treatment until disease progression, death or withdrawal 
from the study as a result of the owner’s decision.
Immunohistochemistry for Pgp expression  
in tumor cells
P-glycoprotein expression in tumor cells was assessed 
using immunohistochemistry adapted from Lee and 
colleagues [13]. Experiments were performed on formalin-
fixed paraffin-embedded samples. Immunohistochemical 
staining was performed automatically using with 
Ventana discovery XT using primary mouse anti-human 
P-glycoprotein Clone C494 antibody (ALX-801–003-C100, 
lab Enzo life sciences) and an HRP peroxydase secondary 
anti-mouse IgG antibody (lab Roche). Normal canine 
liver was used as a positive control for Pgp analysis. 
Non-immune serum substituted to C494 on lymph node 
tissues, was used as a negative control. All controls stained 
appropriately.
Immunohistochemical score (IHS) method was 
then evaluated by a scoring system adapted from Lee and 
colleagues described previously for canine lymphoma 
[13]. The scoring was based on the percentage of stained 
cells and the intensity of the staining. P-glycoprotein 
expression scoring was defined as follows: negative (less 
than 25% stained cells), low (more than 25% but less than 
50% of the tumor cells are stained with a light staining), 
moderate (more than 50% but less than 75% of the tumor 
cells are stained with moderate intensity), high (more 
than 75% are stained with a moderate to high intensity). 
Samples were classified as Pgp-negative (Pgp-) when 
≤ 50% of neoplastic cells in the field had cytoplasmic Pgp 
staining (negative and low); or as Pgp-positive (Pgp+) 
if >50% of neoplastic cells were positive (moderate and 
high). All slides were assessed by one board-certified 
veterinary pathologist (J. Hordeaux), who was blinded to 
the clinical information and treatment group of each dog.
Exploratory biomarkers assessment
Gamma-H2AX cytometry analysis
Cells were collected via fine-needle aspirations from 
three different enlarged lymph nodes on which an average 
of three samples had been performed. Cells were collected 
before treatment initiation, and two, four and 52 hours 
following the first chemotherapy administration. Cell 
viability was measured using Nexcelom Cellometer Auto 
T4 (lab Ozyme Biosciences) and Covalab cell chambers 
as previously described [25]. Gamma-H2AX levels were 
quantified using the flow cytometry technique adapted 
from Huang and colleagues as previously described 
[25, 56]. Cells were ðxed in a 2% formalin solution and 
permeabilized in a 70% cold ethanol solution, then washed 
and rehydrated in PBS, 4% FCS and 0.1% Triton X-100. 
Nuclear H2AX staining was performed using a rabbit anti 
canine-gamma-H2AX antibody (NB100–384; lab Novus 
biologicals) and a secondary antibody (Cy5-goat anti-
rabbit IgG A10931; lab Invitrogen Life Technologies).
DiviTumTM assay of serum Thymidine Kinase 1 
(sTK1) activity measurement
Serum samples were collected for sTK1 activity 
measurement prior to treatment initiation, at the time of 
the best clinical response and at the time of progressive 
disease. Analysis of sTK1 activity was determined 
by a refined ELISA assay, the DiviTumTM assay (lab 
Biovica International, Uppsala, Sweden), according to 
the manufacturer’s instructions (http://biovica.com/), 
as previously described [44]. The absorbance readings 
to DiviTum units per liter (Du/L) were converted using 
the values from standards with known TK activity, with 
a minimum detectable activity for this assay of 20 Du/L. 
Analyses were performed at the Biovica laboratory in 
Uppsala, Sweden, and investigators were blinded to dog 
and tumor data.
Pretreatment plasma D-dimers levels measurement
Plasma D-dimer concentrations were measured 
before treatment initiation using a turbidometric 
immunoassay (Nyco Card Reader II, NYCOMED) 
according to the manufacturer’s instructions.
Study endpoints
The primary endpoints of the study were safety 
and progression-free survival (PFS). Safety analysis 
evaluated the occurrence of TEAEs graded according 
to the VCOG-CTCAE, version 1.1 [27]. Progression-free 
survival was measured from randomization to any of the 
following events, whichever occurred first: progression, 
relapse, death (related to the lymphoma or not), and 
evaluated according to the VCOG criteria v1.0 [55] or 
RECIST criteria v1.0 [28]. Secondary endpoints were 
overall response rate and time to response. Overall 
response rate was defined as the proportion of dogs with 
complete or partial response per VCOG or RECIST 
criteria and time to response was defined as the time from 
Oncotarget683www.oncotarget.com
randomization to best clinical response. The exploratory 
endpoints were the analysis of nuclear expression 
of γ-H2AX, sTK1 activity and pretreatment plasma 
D-dimer level, as biomarker for treatment efficacy and 
prognosis in response to F14512 and etoposide phosphate 
administration.
Statistical analysis
Categorical variables were expressed as numbers 
and percentages, and groups were compared with the 
Chi-square test or, for small numbers, Fisher’s exact 
test. Continuous normally distributed variables, data was 
expressed as mean and SD, and groups were compared 
with t-test or analysis of variance as appropriate. Non-
normally distributed continuous variables were expressed 
as median and range, and groups were compared using 
Wilcoxon rank test or Krustal-Wallis test as appropriate. 
Time to response and PFS data were calculated using 
the Kaplan-Meier method and compared using the log-
rank test. The Cox proportional hazard model was used 
for a univariate screen of all potential predictors of PFS. 
Variables with statistical and clinical significance were 
included in the multivariate analysis using a stepwise 
forward Cox regression model. Results were considered 
statistically significant with a two-sided P value < 0.05. 
The statistical analysis was performed using SPSS 
version 24.0 software (SPSS A, Inc., Chicago, IL, USA).
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